|
|
|
|
||
Re: The Big Enchilada. IT IS ALL ABOUT CRISPR!! Re: Building IP: Patent Application re "Methods and Compositions of Treatment of a Genetic Condition". The patent application claims are not limited to covering only the specific binding sites that are listed in the later claims. If approved as applied for, all the claims would be approved, including the most generic ones. This would cover any use of single guide RNA to bind to any gene, combined with a functional domain that modifies the gene. One patent for CRISPR technology has already been granted to the Broad Institute and MIT, and licensed to Editas, US patent 8697359. Note that this granted patent was filed on Oct. 15, 2013, but it claims priority from Dec. 12, 2012. The original provisional version of the Sangamo patent, which establishes its priority date, was filed on May 15, 2013. The dates are significant, because a new patent law went into effect on March 16, 2013. That law establishes precedence based on "first to file" rather than "first to invent." So the granted CRISPR patent is subject to being challenged based on any evidence that someone came up with the invention before the original filing on 12/12/12 -- any drawings, lab notes, etc. But the Sangamo patent can only be challenged based on prior patent filings. It will be quite interesting to see how this plays out. I think that Sangamo is pursuing a subtle and clever strategy, and its not really clear why they think they might win the fight. Here is the first claim of the granted Broad/MIT patent, which is certainly very close to the first claim in the Sangamo patent application, although much more (perhaps unnecessarily) complicated: 1. A method of altering expression of at least one gene product comprising introducing into a eukaryotic cell containing and expressing a DNA molecule having a target sequence and encoding the gene product an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system comprising one or more vectors comprising: a) a first regulatory element operable in a eukaryotic cell operably linked to at least one nucleotide sequence encoding a CRISPR-Cas system guide RNA that hybridizes with the target sequence, and b) a second regulatory element operable in a eukaryotic cell operably linked to a nucleotide sequence encoding a Type-II Cas9 protein, wherein components (a) and (b) are located on same or different vectors of the system, whereby the guide RNA targets the target sequence and the Cas9 protein cleaves the DNA molecule, whereby expression of the at least one gene product is altered; and, wherein the Cas9 protein and the guide RNA do not naturally occur together. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
71703 | Re: The Big Enchilada. IT IS ALL ABOUT CRISPR!! Re: Building IP: Patent Application re "Methods and Compositions of Treatment of a Genetic Condition". | bin2gray | 1 | 2/26/2015 6:06:57 PM |
71704 | Re: The Big Enchilada. IT IS ALL ABOUT CRISPR!! Re: Building IP: Patent Application re "Methods and Compositions of Treatment of a Genetic Condition". | bin2gray | 10 | 2/26/2015 6:25:00 PM |
71705 | Re: The Big Enchilada. IT IS ALL ABOUT CRISPR!! Re: Building IP: Patent Application re "Methods and Compositions of Treatment of a Genetic Condition". | Oakland53 | 2 | 2/26/2015 6:56:06 PM |